FFilingSight

ConocoPhillips (COP) 10-K Red Flags

Risk signals extracted deterministically from ConocoPhillips’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.

Detected red flags (17)

  • Receivables outpacing revenue: Accounts receivable grew +22.3% YoY vs revenue growth of -28.5%. The +50.8% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
  • Inventory buildup exceeds sales growth: Inventory grew +29.4% vs revenue -28.5%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.
  • Free cash flow deteriorating: FCF declined +29.7% YoY (from $21.68B to $15.25B). With OCF at $19.96B and capex at $4.71B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
  • NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 14 filing(s).
  • Material weakness in internal controls: The term "material weakness" appears in 20 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
  • NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
  • Endogenous analysis: Revenue grew -28.5% but receivables grew +22.3% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
  • Endogenous analysis: Free cash flow deterioration coincides with a -28.9% capex reduction. While lower capex temporarily preserves cash, it may signal underinvestment in growth assets — future revenue capacity could be constrained.
  • Endogenous analysis: Strong cash conversion (OCF > NI) combined with growing deferred revenue provides high forward visibility. The business model appears to generate sustainable, recurring cash flows — a positive structural indicator.
  • 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • 3 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements, Off-balance sheet arrangements.
  • Ongoing high-severity risk language: Material weakness in internal controls.
  • Price $104.73 — downtrend (below 200-DMA); 1-month momentum negative.
  • RSI(14) 25.11 (oversold).
  • Receivables outpacing revenue: Accounts receivable grew +22.3% YoY vs revenue growth of -28.5%. The +50.8% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
  • Inventory buildup exceeds sales growth: Inventory grew +29.4% vs revenue -28.5%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.

Filings & ownership

  • Latest annual report (10-K) filed Feb 17, 2026.
  • Latest quarterly report (10-Q) filed Apr 30, 2026.
  • 8 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference ConocoPhillips; broad institutional reporting.
  • Recent filers include Vermillion Asset Management LLC, Allen Investment Management LLC, INVESTORS TRUST CO /PA.
  • 17 recent 13D activist/beneficial-ownership filings — potential catalyst.
  • 3 recent 13G passive institutional ownership notices.

Full COP analyst report

Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.

View full report →

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.